AZD5423   Click here for help

GtoPdb Ligand ID: 13017

Synonyms: AZD-5423 | compound 1b [PMID: 28937774]
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: AZD5423 was originally reported as a selective glucocorticoid receptor modulator (SGRM) and investigated for anti-inflammatory potential [1,3]. Using a virtual screening strategy it has subsequently been shown to inhibit activation of receptor interacting serine/threonine kinase 3 (RIPK3) [4].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 9
Topological polar surface area 63.16
Molecular weight 487.45
XLogP 3.49
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C[C@@H]([C@@H](C1=CC=CC(=C1)OC)OC2=CC3=C(C=C2)N(C4=CC=C(C=C4)F)N=C3)NC(=O)C(F)(F)F
Isomeric SMILES C[C@@H]([C@@H](C1=CC(=CC=C1)OC)OC2=CC3=C(C=C2)N(N=C3)C4=CC=C(C=C4)F)NC(=O)C(F)(F)F
InChI InChI=1S/C25H21F4N3O3/c1-15(31-24(33)25(27,28)29)23(16-4-3-5-20(12-16)34-2)35-21-10-11-22-17(13-21)14-30-32(22)19-8-6-18(26)7-9-19/h3-15,23H,1-2H3,(H,31,33)/t15-,23-/m0/s1
InChI Key FCNQMDSJHADDFT-WNSKOXEYSA-N
References
1. Gauvreau GM, Boulet LP, Leigh R, Cockcroft DW, Killian KJ, Davis BE, Deschesnes F, Watson RM, Swystun V, Mårdh CK et al.. (2015)
A nonsteroidal glucocorticoid receptor agonist inhibits allergen-induced late asthmatic responses.
Am J Respir Crit Care Med, 191 (2): 161-7. [PMID:25473939]
2. Hemmerling M, Nilsson S, Edman K, Eirefelt S, Russell W, Hendrickx R, Johnsson E, Kärrman Mårdh C, Berger M, Rehwinkel H et al.. (2017)
Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases.
J Med Chem, 60 (20): 8591-8605. [PMID:28937774]
3. Kuna P, Aurivillius M, Jorup C, Prothon S, Taib Z, Edsbäcker S. (2017)
Efficacy and Tolerability of an Inhaled Selective Glucocorticoid Receptor Modulator - AZD5423 - in Chronic Obstructive Pulmonary Disease Patients: Phase II Study Results.
Basic Clin Pharmacol Toxicol, 121 (4): 279-289. [PMID:28212463]
4. Xu CH, Wang JN, Suo XG, Ji ML, He XY, Chen X, Zhu S, He Y, Xie SS, Li C et al.. (2022)
RIPK3 inhibitor-AZD5423 alleviates acute kidney injury by inhibiting necroptosis and inflammation.
Int Immunopharmacol, 112: 109262. [PMID:36166972]